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Abstract
Background: We recently identified selenoprotein P (SeP) as a liver-derived secretory protein that causes insulin resistance
in the liver and skeletal muscle; however, it is unknown whether and, if so, how SeP acts on adipose tissue. The present
study tested the hypothesis that SeP is related to hypoadiponectinemia in patients with type 2 diabetes.
Methodology/Principal Findings: We compared serum levels of SeP with those of adiponectin and other clinical
parameters in 36 patients with type 2 diabetes. We also measured levels of blood adiponectin in SeP knockout mice.
Circulating SeP levels were positively correlated with fasting plasma glucose (r=0.35, P=0.037) and negatively associated
with both total and high-molecular adiponectin in patients with type 2 diabetes (r=20.355, P=0.034; r=20.367, P=0.028).
SeP was a predictor of both total and high-molecular adiponectin, independently of age, body weight, and quantitative
insulin sensitivity index (b=20.343, P=0.022; b=20.357, P=0.017). SeP knockout mice exhibited an increase in blood
adiponectin levels when fed regular chow or a high sucrose, high fat diet.
Conclusions/Significance: These results suggest that overproduction of liver-derived secretory protein SeP is connected
with hypoadiponectinemia in patients with type 2 diabetes.
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Introduction
We have recently identified selenoprotein P (SeP) as a liver-
derived secretory protein that causes insulin resistance and
hyperglycemia in patients with type 2 diabetes [1]. SeP (encoded
by the SEPP1 gene in humans) is a plasma protein primarily
produced by the liver [2]. SeP, which contains 10 selenocysteine
residues per polypeptide, functions as a selenium transport protein
[3,4]; however, its role in glucose homeostasis was unknown. SeP
has been emerged from human liver screening for secretory
proteins whose hepatic expression levels are significantly correlat-
ed with insulin resistance [1]. We have found that blood levels of
SeP are elevated in rodents and patients with type 2 diabetes, and
that SeP impairs cellular insulin signal transduction and
dysregulates glucose metabolism in both hepatocytes and myo-
cytes, at least partly, by inactivating adenosine monophosphate-
activated protein kinase (AMPK). These findings suggest that SeP
functions as a ‘‘hepatokine’’ causing insulin resistance in the liver
and skeletal muscle of patients with type 2 diabetes. However, it
was still unclear whether SeP acts directly on adipose tissue or
adipocytes.
Adiponectin is an adipocyte-derived secretory protein that
improves systemic glucose tolerance and protects the vasculature
from atherosclerosis [5,6,7,8]. Circulating levels of adiponectin
decrease in patients who are obese, and those with insulin
resistance and type 2 diabetes [9,10]. Additionally, hypoadipo-
nectinemia is an independent risk factor for developing type 2
diabetes and cardiovascular disease [11,12,13,14]. Three different
forms of adiponectin have been identified: a high molecular weight
(HM) form, a low molecular weight form, and a trimeric form
[15,16]. HM adiponectin possesses the most potent insulin-
sensitizing activity and is more closely associated with the
development of type 2 diabetes than total adiponectin [17].
Adiponectin gene expression is regulated by multiple transcrip-
tional factors and stimulators including peroxisome proliferator-
activated receptor (PPARc) [18,19]; however, the molecular
mechanisms by which adiponectin production is suppressed in
patients with type 2 diabetes are not fully understood.
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34952We hypothesized that SeP acted on adipocytes and affected
adiponectin production. To test this, we compared serum SeP
levels with those of adiponectin in patients with type 2 diabetes.
We also measured blood levels of adiponectin in SeP knockout
mice to determine whether SeP contributed to hypoadiponectine-
mia induced by a high calorie diet.
Results
Circulating selenoprotein P is associated with fasting
plasma glucose and total and high-molecular
adiponectin levels in patients with type 2 diabetes
The clinical and laboratory variables of the study subjects are
shown in Table 1. Circulating SeP levels were significantly
correlated with fasting plasma glucose (r=0.35, P=0.037), as we
described previously [1] (Fig. 1). Furthermore, serum SeP
concentrations were negatively associated with both total and
HM adiponectin levels in patients with type 2 diabetes (r=0.355,
P=0.034; r=0.367, P=0.028) (Fig. 2). No significant correlation
was found between SeP and age, body weight, body mass index,
liver function, high-sensitivity C-reactive proteins (hsCRP), or
QUICKI (Table 2).
Circulating SeP is an independent predictor of circulating
adiponectin levels in patients with type 2 diabetes
We performed a linear regression analysis of HM adiponectin
and total adiponectin concentrations to determine clinical factors
related to hypoadiponectinemia in patients with type 2 diabetes
(Table 3 and Table 4). Serum concentrations of both HM and
total adiponectin were negatively associated with age, body weight,
QUICKI, and SeP. We generated multivariate linear regression
models using HM and total adiponectin as the dependent variable
to clarify the contribution of SeP on the decrease in adiponectin
concentrations. As shown in Table 5 and Table 6, we found that
SeP was a predictor of HM and total adiponectin, independently
of age, body weight, and QUICKI.
Blood levels of adiponectin are elevated in SeP-deficient
mice
We measured blood levels of adiponectin in SeP knockout mice
fed a high sucrose, high fat diet to examine whether SeP was
related to the development of hypoadiponectinemia induced by
obesity and diabetes. We previously reported that SeP-deficient
mice are protected from insulin resistance and adipocyte
hypertrophy induced by a high sucrose, high fat diet, although
body weight is unaffected [1]. As shown in Figure 3, SeP-deficient
mice exhibited an increase in blood adiponectin levels when fed
regular chow and the high sucrose, high fat diet. These results
indicate that SeP is connected with the onset of hypoadiponecti-
nemia induced by a high fat, high sucrose diet in vivo.
Expression of genes involved in adipogenesis and
inflammation in adipose tissue of SeP knockout mice
We assessed levels of gene expression involved in adipogenesis
and inflammation in the adipose tissue of SeP knockout mice fed a
high fat, high sucrose diet (Fig. 4). Gene expression levels for
CCAAT/enhancer-binding protein-a (C/EBP-a) and CCAAT/
enhancer-binding protein-b (C/EBP-b) were up-regulated in SeP-
deficient mice. Gene expression levels for adiponectin tended to be
increased in the knockout mice. Expression of genes for PPARc,
monocyte chemoattractant protein-1 (MCP1), interleukin-6 (IL-6),
and tumor necrosis factor-a (TNF-a) was unchanged.
Discussion
The results indicate that circulating SeP, a liver-derived
secretory protein, is an independent predictor of adiponectin in
patients with type 2 diabetes. Furthermore, our findings reveal that
SeP-deficient mice were protected from hypoadiponectinemia
regardless of nutritional status. These findings lead us to conclude
Figure 1. Correlation between selenoprotein P and glucose
concentrations in patients with type 2 diabetes. Pearson’s
analysis r and P values are shown.
doi:10.1371/journal.pone.0034952.g001
Table 1. Clinical and laboratory variables.
Characteristics
n 36
Age (years) 58.4612.4
Gender (M/F) 26/10
Body weight (kg) 64.3611.3
BMI (kg/m
2) 24.563.8
Fasting plasma glucose (mg/dL) 154.6642.5
HbA1c (%) 8.962.1
Fasting immunoreactive insulin (mU/mL) 7.0664.27
QUICKI 0.3760.05
AST (IU/L) 24.8616.3
ALT (IU/L) 34.5634.5
Total cholesterol (mg/dL) 192.1633.7
Triglyceride (mg/dL) 124.6646.9
High-sensitivity C-reacitive protein (mg/dL) 0.1060.10
Selenoprotein P (mg/mL) 5.661.2
Total adiponectin (mg/mL) 4.764.2
High-molecular weight adiponectin (mg/mL) 1.962.6
Data are means6SD. BMI, body mass index; HbA1c, glycosylated hemoglobin;
QUICKI, quantitative insulin sensitivity index; AST, aspartate aminotransferase;
ALT, alanine aminotransferease.
doi:10.1371/journal.pone.0034952.t001
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development of hypoadiponectinemia observed in patients with
type 2 diabetes.
We have previously reported that serum levels of SeP in normal
subjects and type 2 diabetic patients were 5.161.7 and 6.760.9,
respectively [1]. In the current study, levels of serum SeP in
patients with type 2 diabetes were 5.661.2 mg/mL (Table 1). The
present values were relatively lower than those in our previous
report. This might be explained by the fact that the severity of
obesity and insulin resistance of the patients in the current study
was lower than those in our previous study. More recently, Yang et
al. have also shown that serum concentrations of SeP were 3-fold
up-regulated in Korean patients with type 2 diabetes compared
with normal subjects [20]. The molecular mechanisms by which
type 2 diabetes increases blood levels of SeP are not fully
understood. However, several lines of evidence has shown that
insulin dramatically suppresses the production of SeP in the
hepatocytes [1,21,22], suggesting that decreased insulin action in
the liver may induces the elevation of circulating SeP in patients
with type 2 diabetes.
We have previously showed that gene expression levels for SeP
in the liver are positively correlated with the severity of insulin
resistance measured by glucose clamp experiments in patients with
type 2 diabetes [1]. However, in the current study, there were no
Figure 2. Correlation between serum levels of selenoprotein P
and total adiponectin (A) and high-molecular adiponectin (B)
in patients with type 2 diabetes. Pearson’s analysis r and P values
are shown.
doi:10.1371/journal.pone.0034952.g002
Table 2. Linear regression analysis of selenoprotein P
concentrations with clinical parameters.
SeP concentration
p value r
2
Age 0.431 0.018
Body weight 0.466 0.016
BMI 0.835 0.001
Fasting plasma glucose 0.037
* 0.122
HbA1c 0.391 0.022
Fasting immunoreactive insulin 0.424 0.020
QUICKI 0.552 0.010
AST 0.874 0.001
ALT 0.961 0.000
Total cholesterol 0.842 0.001
Triglyceride 0.43 0.018
High-sensitivity C-reacitive protein 0.871 0.0007
Total adiponectin 0.034
* 0.126
High-molecular weight adiponectin 0.028
* 0.135
*p,0.05.
see Table 1 for abbreviations.
doi:10.1371/journal.pone.0034952.t002
Table 3. Linear regression analysis of high-molecular
adiponectin concentrations with clinical parameters.
High-molecular adiponectin
concentration
p value r
2
Age 0.013
* 0.168
Body weight 0.035
* 0.125
BMI 0.158 0.058
Fasting plasma glucose 0.749 0.003
HbA1c 0.798 0.002
Fasting immunoreactive insulin 0.198 0.051
QUICKI 0.027
* 0.135
AST 0.646 0.006
ALT 0.325 0.029
Total cholesterol 0.378 0.023
Triglyceride 0.066 0.096
Total adiponectin 0.0001
* 0.99
High-sensitivity C-reacitive protein 0.327 0.029
Selenoprotein P 0.028
* 0.135
*p,0.05.
See TABLE 1 for abbreviations.
doi:10.1371/journal.pone.0034952.t003
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insulin resistance such as QUICKI and fasting immunoreactive
insulin. This discrepancy might depend on the fact that the
patients in the current study had a low degree of obesity and
insulin resistance. Unlike Western subjects, Japanese patients with
type 2 diabetes are characterized by decreased insulin secretion
rather than insulin resistance. Hence, the clinical markers such as
QUICKI, those are estimated by blood insulin levels, might not
accurately reflect the sevirity of insulin resistance in these patients.
Additional studies by using glucose clamp experiments will provide
information of the relationship between serum SeP concentrations
and the sevirity of insulin resistance in Japanese patients with type
2 diabetes.
The present study uncovers hyperadiponectinemia in SeP
knockout mice fed a high sucrose, high fat diet. In our previous
study, SeP knockout mice show an attenuation of adipocyte
hypertrophy and an improvement of glucose tolerance and insulin
resistance when on a high fat, high sucrose diet [1]. However, the
notable finding in the current study was that blood levels of
adiponectin in SeP knockout mice fed a high sucrose, high fat diet
did not completely reach to those in wild-type mice fed a normal
chow. In addition, the present findings in humans showed that the
correlation between SeP and adiponectin is not strong, explaining
only 13% of the variance in adiponectin levels. These results
strongly suggest that the contribution of SeP on hypoadiponecti-
nemia is only partial, and that other factors except the elevation of
circulating SeP also participate in the development of hypoadipo-
nectinemia in type 2 diabetes.
More recently, Schoenmakers et al. reported an elevation in
blood adiponectin and enhanced insulin signaling in patients with
markedly reduced expression of plasma SeP due to a genetic defect
in the SECISBP2 gene that encodes selenocysteine insertion
sequence-binding protein 2 [23]. These patients have compound
heterozygous SECISBP2 defects that result in diminished synthesis
of most known selenoproteins, such as SeP. We cannot exclude the
possibility that defects in selenoproteins other than SeP contrib-
uted to the phenotypes in these patients, but their metabolic
findings were in good agreement with those in SeP knockout mice.
Thus, we believe that the reduction in plasma SeP contributes, at
least in part, to the hyperadiponectinemia observed in these
patients with a genetic defect in the SECISBP2 gene.
Table 4. Linear regression analysis of total adiponectin
concentrations with clinical parameters.
Total adiponectin concentration
p value r
2
Age 0.009
* 0.185
Body weight 0.035
* 0.124
BMI 0.165 0.056
Fasting plasma glucose 0.728 0.007
HbA1c 0.932 0.0002
Fasting immunoreactive insulin 0.197 0.052
QUICKI 0.030
* 0.132
AST 0.557 0.010
ALT 0.250 0.040
Total cholesterol 0.416 0.020
Triglyceride 0.061 0.099
High-molecular adiponectin 0.0001
* 0.99
High-sensitivity C-reacitive protein 0.317 0.030
Selenoprotein P 0.034
* 0.126
*p,0.05.
See TABLE 1 for abbreviations.
doi:10.1371/journal.pone.0034952.t004
Table 5. Multivariate regression analysis of high-molecular
adiponectin concentration as a dependent variable.
High-molecular adiponectin
concentration
b p value
Age 0.310 0.06
Body weight 20.033 0.848
QUICKI 0.362 0.022
*
Selenoprotein P 20.357 0.017
*
*p,0.05.
QUICKI, quantitative insulin sensitivity index.
doi:10.1371/journal.pone.0034952.t005
Table 6. Multivariate regression analysis of total adiponectin
concentration as a dependent variable.
Total adiponectin concentration
b p value
Age 0.337 0.042
Body weight 20.023 0.891
QUICKI 0.356 0.024
*
selenoprotein P 20.343 0.022
*
*p,0.05.
QUICKI, quantitative insulin sensitivity index.
doi:10.1371/journal.pone.0034952.t006
Figure 3. Blood levels of adiponectin in selenoprotein P-
knockout and wild-type mice fed regular chow or a high fat,
high sucrose diet (n=5–10). Sixteen week old male mice were fed a
high fat, high sucrose diet for 16 weeks. Data represents the means 6
SEM. *p,0.05, **p,0.01, vs. wild-type mice.
doi:10.1371/journal.pone.0034952.g003
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ponectinemia are associated with low-grade inflammation, espe-
cially in the adipose tissue [24]. However, the current study
showed no correlation between SeP and hsCRP, a representative
marker of low-grade inflammation in Japanese patients with type 2
diabetes. Moreover, gene expression levels involved in inflamma-
tion were unchanged in the adipose tissue of SeP knockout mice.
These results suggest that SeP is not strongly connected with low-
grade inflammation observed in type 2 diabetes. More recently,
however, Yang et al. have reported that blood levels of SeP are
positively and strongly correlated with those of hsCRP in Korean
people with type 2 diabetes [20]. The discrepancy between Yang’s
report and our study might be associated with the fact that our
patients in Japan had lower degree of obesity, insulin resistance,
and inflammation. Further investigation is necessary to elucidate
the action of SeP on low-grade inflammation in the adipose tissue.
A limitation of our study was that we did not measure blood
concentrations of selenium in our patients. Several lines of
evidence indicate that selenium supplementation increases SeP
blood levels [25,26,27]. Furthermore, serum selenium levels are
positively correlated with SeP levels in humans [28,29] Additional
studies on a larger number of samples are needed to clarify the
connections among selenium, SeP, and adiponectin.
In conclusion, our results suggest that the elevation of
hepatokine SeP is connected with hypoadiponectinemia in type
2 diabetic conditions. Further cellular or animal experiments are
needed to investigate whether SeP directly acts on the adipocytes
or adipose tissue.
Materials and Methods
Ethics Statement
All patients provided written informed consent for this study.
The experimental protocol was approved by the Ethics Screening
Committee of Kanazawa University Hospital (Approval
NO. 1123), and the study was conducted in accordance with the
Declaration of Helsinki.
The animal study was carried out in accordance with the
Guidelines on the Care and Use of Laboratory Animals issued by
Kanazawa University. The protocol was approved by the ethical
committee of Kanazawa University (Approval NO. 50202). All
surgery was performed under sodium pentobarbital anesthesia,
and all efforts were made to minimize suffering.
Figure 4. Expression of genes involved in adipogenesis and inflammation in the adipose tissue of selenoprotein P-knockout and
wild-type mice fed a high fat, high sucrose diet (n=5–10). RNA was isolated from epididymal fat of mice. Data represents the means 6 SEM.
+p,0.1, *p,0.05, **p,0.01, vs. wild-type mice.
doi:10.1371/journal.pone.0034952.g004
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Blood samples were obtained from 36 patients with type 2
diabetes, who were admitted to Kanazawa University Hospital
from April 2006 to March 2007. Some patients in our previous
study [1] were involved in the current study. Patients with type 2
diabetes were diagnosed based on criteria established by an expert
committee on the diagnosis and classification of diabetes mellitus.
Patients were treated with diet therapy alone or with sulfonylureas
or insulin; no patient received any other oral hypoglycemic agents,
such as pioglitazone or a biguanide. Furthermore, participants
receiving statins, angiotensin-converting enzyme inhibitors, or
angiotensin II receptor blockers were excluded. After an overnight
fast, venous blood samples were withdrawn from each patient.
Assays
Serum SeP levels were measured by ELISA using two
monoclonal antibodies, as described previously [30]. Serum levels
of total and HM adiponectin were measured using ELISA kits
purchased from Ostuka (Tokyo, Japan) and Fujirebio (Tokyo,
Japan), respectively. The immunonephelometric method was used
to measure high-sensitivity C-reactive protein (hsCRP). The
immunoenzymometric assays used for quantifying insulin were
conducted with kits purchased from Tosoh (Shunan, Japan). The
quantitative insulin sensitivity index (QUICKI) was used as a
convenient index of insulin resistance [31]. QUICKI values were
calculated using the following formula:
QUICKI~1= log fasting plasma glucose mU=mL ðÞ ½  f
zlog fasting insulin mmol=L ðÞ ½  g
Mouse study
Sepp1-deficient mice were produced by homologous recombi-
nation using genomic DNA cloned from a Sv-129 P1 library, as
described previously [3]. Sepp1-deficient mice were backcrossed to
C57/BL6 for up to three generations. Sixteen-week-old male mice
were fed a high fat, high sucrose diet for 16 weeks (n=5–10). After
a 12-h fast, blood samples were obtained. The high fat, high
sucrose diet (D03062301) was purchased from Research Diets
(New Brunswick, NJ, USA). Sepp1-deficient mice experiments were
performed using frozen blood samples adipose tissue obtained
from our previous study [1]. Serum adiponectin levels were
determined using a mouse adiponectin ELISA kit (Otsuka),
according to the manufacturers’ instructions.
Real-Time Quantitative Polymerase Chain Reaction
Total RNA was extracted from each epididymal adipose tissue
using the RNeasy Lipid Tissue Mini Kit (Qiagen). cDNA was
synthesized from 100 ng of total RNA using a high-capacity
cDNA Archive Kit (Applied Biosystems). Real-time quantitative
Polymerase Chain Reaction (PCR) was performed for C/EBP-a,
C/EBP-b, PPARc, adiponectin, MCP-1, IL-6, and TNF-a, using
mRNA using the ABI Prism 7900 Sequence Detection System
(Applied Biosystems) as previously described [32]. The sets of
primers and TaqMan probes were proprietary to Applied
Biosystems (TaqMan Gene Expression Assays product). To
control for variation in the amount of DNA available for PCR
in the different samples, gene expression of the target sequence
was normalized in relation to the expression of an endogenous
control, 18S rRNA (TaqMan Control Reagent Kit; Applied
Biosystems). The PCR conditions were one cycle at 50uC for
2 min, 95uC for 10 min, followed by 50 cycles at 95uC for 15 s
and 58uC for 1 min.
Statistical Analysis
Data are shown as means 6 SDs for the human study, unless
stated otherwise. The relationship between individual variables
was analyzed by Pearson’s simple correlation, and multiple
regression using a forced entry manner. We report squared
correlation coefficients and P values for the univariate linear
regression analysis and coefficients and P values for the multiple
linear regression analysis. Data are shown as means6SEs for the
mouse studies. Data involving more than two groups were assessed
by analysis of variance. The Japanese Windows edition of SPSS
(ver. 11.0; SPSS, Inc., Chicago, IL, USA) was used for statistical
analyses. P values,0.05 were considered to indicate statistical
significance.
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